These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16949492)

  • 1. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
    Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK; Loshchits NV
    Ter Arkh; 2004; 76(3):62-8. PubMed ID: 15108463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
    Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure].
    Ma QL; Xie Y; Zhang SD
    Hunan Yi Ke Da Xue Xue Bao; 2002 Dec; 27(6):527-9. PubMed ID: 12658930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
    Leonardo F; Fragasso G; Rossetti E; Dabrowski P; Pagnotta P; Rosano GM; Chierchia SL
    Cardiologia; 1999 Dec; 44(12):1065-9. PubMed ID: 10687257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
    Multicentral Collaborative Group on Trimetazidine (Phase IV)
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep; 33(9):793-5. PubMed ID: 16266453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G; Bunc M; Vrtovec B
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):31-6. PubMed ID: 19966175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
    De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
    J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical training in patients with chronic heart failure of ischemic origin: effect on exercise capacity and left ventricular remodeling.
    Klecha A; Kawecka-Jaszcz K; Bacior B; Kubinyi A; Pasowicz M; Klimeczek P; Banyś R
    Eur J Cardiovasc Prev Rehabil; 2007 Feb; 14(1):85-91. PubMed ID: 17301632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of trimetazidine on p-wave duration and dispersion in heart failure patients.
    Gunes Y; Tuncer M; Guntekin U; Akdag S; Gumrukcuoglu HA
    Pacing Clin Electrophysiol; 2009 Feb; 32(2):239-44. PubMed ID: 19170914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.